Filtering

Page: () 1 2 3 ()
JCC: ECCO Topical ReviewEuropean Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease
Year: 2016
Source: JCC: ECCO Topical Review
Authors: Florian Rieder, Giovanni Latella, Fernando Magro, Elif S. Yuksel, Peter D. R. Higgins, Antonio Di Sabatino, Jessica R. de Bruyn, Jordi Rimola, Jorge Brito, Dominik Bettenworth, Gert van Assche, Willem Bemelman, Andre d’Hoore, Gianluca Pellino, Axel U. Dignass

This ECCO topical review of the European Crohn’s and Colitis Organisation [ECCO] focused on prediction, diagnosis, and management of fibrostenosing Crohn’s disease [CD]. The objective was to achieve evidence-supported, expert consensus that provides guidance for clinical practice.

JCC: Volume 10, Issue 8, 2016European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease
Year: 2016
Source: JCC: Volume 10, Issue 8, 2016
Authors: Florian Rieder, Giovanni Latella, Fernando Magro, Elif S. Yuksel, Peter D. R. Higgins, Antonio Di Sabatino, Jessica R. de Bruyn, Jordi Rimola, Jorge Brito, Dominik Bettenworth, Gert van Assche, Willem Bemelman, Andre d’Hoore, Gianluca Pellino, Axel U. Dignass

This ECCO topical review of the European Crohn’s and Colitis Organisation [ECCO] focused on
prediction, diagnosis, and management of fibrostenosing Crohn’s disease [CD]. The objective was
to achieve evidence-supported, expert consensus that provides guidance for clinical practice

JCC: Volume 11, Issue 9, 2017European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
Year: 2017
Source: JCC: Volume 11, Issue 9, 2017
Authors: Patrick F. van Rheenen, Marina Aloi, Irit Avni Biron, Katrine Carlsen, Rachel Cooney, Salvatore Cucchiara, Garret Cullen, Johanna C. Escher, Jaroslaw Kierkus, James O. Lindsay, Eleftheria Roma, Richard K. Russell, Joanna Sieczkowska-Golub, Marcus Harbordl

This European Crohn’s and Colitis Organisation [ECCO] topical review focuses on the transition of adolescents with inflammatory bowel disease [IBD] from child-centred to adult-oriented care. The aim was to provide evidence-supported, expert consensus for health professionals taking part in the transition.

JCC: Volume 12, Issue 1, 2018European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease
Year: 2017
Source: JCC: Volume 12, Issue 1, 2018
Authors: Glen Doherty, Konstantinos H. Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P. Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis

Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and Crohn’s Disease [CD]. For each major class of IBD medications [5-aminosalicyclates, immunomodulators, and biologic agents], used alone or in combination, there is a risk of relapse following reduction or cessation of treatment. A consensus expert panel convened by the European Crohn’s and Colitis Organisation [ECCO] reviewed the published literature and agreed a series of consensus practice points. The objective of the expert consensus is to provide evidence-based guidance for clinical practice so that physicians can make informed decisions in partnership with their patients. The likelihood of relapse with stopping each class of IBD medication is reviewed. Factors associated with an altered risk of relapse with withdrawal are evaluated, and strategies to monitor and allow early identification of relapse are considered. In general, patients in clinical, biochemical, and endoscopic remission are more likely to remain well when treatments are stopped. Reintroduction of the same treatment is usually, but not always, successful. The decision to stop a treatment needs to be individualized, and shared decision making with the patient should take place.



JCC: Volume 9, Issue 1, 2015European evidence based consensus on surgery for ulcerative colitis
Year: 2014
Source: JCC: Volume 9, Issue 1, 2015
Authors: Tom Øresland , Willem A. Bemelman, Gianluca M. Sampietro, Antonino Spinelli, Alastair Windsor, Marc Ferrante, Philippe Marteau, Oded Zmora, Paulo Gustavo Kotze, Eloy Espin-Basany, Emmanuel Tiret, Giuseppe Sica, Yves Panis, Arne E. Faerden, Livia Biancone, Imerio Angriman, Zuzana Serclova, Anthony de Buck van Overstraeten, Paolo Gionchetti, Laurents Stassen, Janindra Warusavitarne, Michel Adamina, Axel Dignass, Rami Eliakim, Fernando Magro, André D’Hoore

The goal of this consensus initiated by the European Crohn's and Colitis Organisation (ECCO) was to establish European consensus guidelines for the surgical treatment of ulcerative colitis. The strategy to reach the consensus involved several steps and follows the standard operating procedures for consensus guidelines of ECCO. An open call for chairs and participants for this consensus was made (see acknowledgements and www.ecco-ibd). Participants were selected by the Guidelines' Committee of ECCO (GuiCom) on the basis of their publication record and a personal statement. Four working groups (WGs) were formed: WG 1 on the preoperative phase, WG 2 on the intraoperative phase, WG 3 on the postoperative phase and WG 4 on special situations. Participants were asked to answer relevant questions on current practice and areas of controversy related to the surgical treatment of ulcerative colitis based on their experience as well as evidence from the literature (Delphi procedure).

JCC: Volume 9, Issue 11, 2015European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Year: 2015
Source: JCC: Volume 9, Issue 11, 2015
Authors: Vito Annese, Laurent Beaugerie, Laurence Egan, Livia Biancone, Claus Bolling, Christian Brandts, Daan Dierickx, Reinhard Dummer, Gionata Fiorino, Jean Marc Gornet, Peter Higgins, Konstantinos H. Katsanos, Loes Nissen, Gianluca Pellino, Gerhard Rogler, Franco Scaldaferri, Edyta Szymanska, Rami Eliakim

Due to the important clinical problem that the risk of malignancy in patients with IBD represents for physicians treating IBD, ECCO planned to initiate a programme to develop a specific Guideline for malignancy. 
The aim of this consensus is to 
establish Guidelines for managing the risk of malignancy, treatment in the event of malignancy and therapy of IBD in the context of a past or current history of malignancy.

JCC: ViewpointHow to Apply for and Secure EU Funding for Collaborative IBD Research Projects
Year: 2016
Source: JCC: Viewpoint
Authors: Jack Satsangi, Olivier Kitten, Marcela Chavez, Rahul Kalla, Nadege Prel, Marie-Alice Meuwis, Stephanie Scott, Illaria Bonetti, Nicholas T. Ventham, Edouard Louis

The European Union offers opportunities for high-level of funding of collaborative European research. Calls are regularly published: after the end of the FP7 funding programme the new round of Horizon 2020 calls started in 2015. Several topics are relevant to inflammatory bowel disease (IBD) challenges, including chronic disease management, biomarker discovery and new treatments developments. The aim of this Viewpoint article is to describe the new Horizon 2020 instrument and the project submission procedures, and to highlight these through the description of tips and tricks, taking advantage of four examples of successful projects in the field of IBD: the SADEL, IBD-BIOM, IBD Character and BIOCYCLE projects.

JCC: ViewpointMaking a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics
Year: 2017
Source: JCC: Viewpoint
Authors: Konstantinos H. Katsanos, Eugeni Domènech, Jean-François Rahier, Uri Kopylov, Gionata Fiorino, Gerhard Rogler, Edouard Louis, Shomron Ben-Horin
JPGN: Volume 67, Issue 2, 2018Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Year: 2018
Source: JPGN: Volume 67, Issue 2, 2018
Authors: Turner, Dan; Ruemmele, Frank M.; Orlanski-Meyer, Esther; Griffiths, Anne M.; de Carpi, Javier Martin; Bronsky, Jiri; Veres, Gabor; Aloi, Marina; Strisciuglio, Caterina; Braegger, Christian P.; Assa, Amit; Romano, Claudio; Hussey, Séamus; Stanton, Michael; Pakarinen, Mikko; de Ridder, Lissy; Katsanos, Konstantinos; Croft, Nick; Navas-López, Victor; Wilson, David C.; Lawrence, Sally; Russell, Richard K.

These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.

JPGN: Volume 67, Issue 2, 2018Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Year: 2018
Source: JPGN: Volume 67, Issue 2, 2018
Authors: Turner, Dan; Ruemmele, Frank M.; Orlanski-Meyer, Esther; Griffiths, Anne M.; de Carpi, Javier Martin; Bronsky, Jiri; Veres, Gabor; Aloi, Marina; Strisciuglio, Caterina; Braegger, Christian P.; Assa, Amit; Romano, Claudio; Hussey, Séamus; Stanton, Michael; Pakarinen, Mikko; de Ridder, Lissy; Katsanos, Konstantinos H.; Croft, Nick; Navas-López, Víctor Manuel; Wilson, David C.; Lawrence, Sally; Russell, Richard K.

Background and aim:

Acute severe colitis (ASC) is one of the few emergencies in pediatric gastroenterology. Tight monitoring and timely medical and surgical interventions may improve outcomes and minimize morbidity and mortality. We aimed to standardize daily treatment of ASC in children through detailed recommendations and practice points which are based on a systematic review of the literature and consensus of experts.

Methods:

These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Fifteen predefined questions were addressed by working subgroups. An iterative consensus process, including 2 face-to-face meetings, was followed by voting of the national representatives of ECCO and all members of the Paediatric Inflammatory Bowel Disease (IBD) Porto group of ESPGHAN (43 voting experts).

Results:

A total of 24 recommendations and 43 practice points were endorsed with a consensus rate of at least 91% regarding diagnosis, monitoring, and management of ASC in children. A summary flowchart is presented based on daily scoring of the Paediatric Ulcerative Colitis Activity Index. Several topics have been altered since the previous 2011 guidelines and from those published in adults.

Discussion:

These guidelines standardize the management of ASC in children in an attempt to optimize outcomes of this intensive clinical scenario

JPGN: Volume 55, Issue 3, 2012Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines
Year: 2012
Source: JPGN: Volume 55, Issue 3, 2012
Authors: Turner, Dan; Levine, Arie; Escher, Johanna C.; Griffiths, Anne M.; Russell, Richard K.; Dignass, Axel; Dias, Jorge Amil; Bronsky, Jiri; Braegger, Christian P.; Cucchiara, Salvatore; de Ridder, Lissy; Fagerberg, Ulrika L.; Hussey, Séamus; Hugot, Jean-Pierre; Kolacek, Sanja; Kolho, Kaija Leena; Lionetti, Paolo; Pærregaard, Anders; Potapov, Alexander; Rintala, Risto; Serban, Daniela E.; Staiano, Annamaria; Sweeny, Brian; Veerman, Gigi; Veres, Gabor; Wilson, David C. Ruemmele, Frank M.

The aim of this new consensus is to establish standards for the diagnosis and management of Paediatric UC. It will include the use of immunosuppressors and biologics.

JCC: Volume 7, Issue 9, 2013N-ECCO Consensus statements on the European nursing roles in caring for patients with CD or UC (2013)
Year: 2013
Source: JCC: Volume 7, Issue 9, 2013
Authors: M. O'Connor, P. Bager, J. Duncan, J. Gaarenstroo, L. Younge, P. Détré, F. Bredin, L. Dibley, A. Dignass, M. Gallego Barrero, K. Greveson, M. Hamzawi, N. Ipenburg, D. Keegan, M. Martinato, F. Murciano Gonzalo, S. Pino Donnay, T. Price, A. Ramirez Morros, M. Verwey, L. White, C.J. van de Woude

The N-ECCO Consensus provides clarity on the different nursing roles in caring for patients with Crohn’s disease and ulcerative colitis within Europe. The intention is to identify the position of IBD nurses and provide a consensus on the ideal standard of nursing care that patients with IBD can expect, irrespective of level of training or title.

Thieme E-Journals - EndoscopyOMED-ECCO Consensus on small bowel endoscopy (Edition 2009)
Source: Thieme E-Journals - Endoscopy
Authors: Bourreille, A.; Ignjatovic, A.; Aabakken, L.; Loftus, E.; Eliakim, R.; Pennazio, M.; Bouhnik, Y.; Seidman, E.; Keuchel, M.; Albert, J.; Ardizzone, S.; Bar-Meir, S.; Bisschops, R.; Despott, E.; Fortun, P.; Heuschkel, R.; Kammermeier, J.; Leighton, J.; Mantzaris, G.; Moussata, D.; Lo, S.; Paulsen, V.; Panés, J.; Radford-Smith, G.; Reinisch, W.; Rondonotti, E.; Sanders, D.; Swoger, J.; Yamamoto, H.; Travis, S.; Colombel, J.-F.; Van Gossum, A.

Crohn’s disease and ulcerative colitis are lifelong diseases seen predominantly in the developed countries of the world.

Whereas ulcerative colitis is a chronic inflammatory condition causing diffuse and continuous mucosal inflammation of the colon, Crohn’s disease is a heterogeneous entity comprised of several different phenotypes, but can affect the entire gastrointestinal tract. A change in diagnosis from Crohn’s disease to ulcerative colitis during the first year of illness occurs in about 10 % – 15 % of cases. Inflammatory bowel disease (IBD) restricted to the colon that cannot be characterized as either ulcerative colitis or Crohn’s disease is termed IBD-unclassified (IBDU).

The advent of capsule and both single- and double-balloon-assisted enteroscopy is revolutionizing small-bowel imaging and has major implications for diagnosis, classification, therapeutic decision making and outcomes in the management of IBD. The role of these investigations in the diagnosis and management of IBD, however, is unclear.

This document sets out the current Consensus reached by a group of international experts in the fields of endoscopy and IBD at a meeting held in Brussels, 12–13th December 2008, organised jointly by the European Crohn’s and Colitis Organisation (ECCO) and the Organisation Mondiale d’Endoscopie Digestive (OMED). The Consensus is grouped into seven sections: definitions and diagnosis; suspected Crohn’s disease; established Crohn’s disease; IBDU; ulcerative colitis (including ileal pouch–anal anastomosis [IPAA]); paediatric practice; and complications and unresolved questions.

Consensus guideline statements are followed by comments on the evidence and opinion. Statements are intended to be read in context with qualifying comments and not read in isolation.


JCC: ViewpointPatient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations
Year: 2016
Source: JCC: Viewpoint
Authors: Laurent Peyrin-Biroulet, Sanna Lönnfors, Xavier Roblin, Silvio Danese, Luisa Avedano

Background and Aim:

The aim of this survey was to find out the patients’ perspectives concerning biosimilars.

Methods:

An online survey consisting of 14 questions was made available between November 2014 and October 2015. Only respondents who had heard of biosimilars were asked to respond the final twelve questions.

Results:

A total of 1181 patients responded. Of these, 38% had heard of biosimilars. The respondents worried about biosimilars’ safety profile [47.0%], efficacy [40.3%], and molecular basis [35.0%]. Only 25.2% of the respondents had no concerns about biosimilars. Just over half [55.9%] of the respondents thought that the lower cost of the biosimilars should not come before their safety and efficacy. Only 12.5% of respondents felt that extrapolation made sense. The survey showed that 39.9% felt that patients should be systematically informed, and 26.7% felt that patient associations should be informed and able to give their opinions. It also revealed that 20.9% of the respondents would be against the idea of interchangeability if the patient was not aware; 65.7% of the respondents would want to know whether they were receiving the reference drug or the biosimilar, and have all necessary information in writing before the drug was administered. Only 31.0% of the respondents would be fully confident about biosimilars, even if they were prescribed and explained by the treating physician.

Conclusions:

Most patients were not familiar with biosimilars, and those who were had doubts and concerns about the biosimilars’ safety and efficacy. The patients wished to be informed and involved in decision-making concerning biosimilars.

JCC: Volume 11, Issue 12, 2017Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]
Year: 2017
Source: JCC: Volume 11, Issue 12, 2017
Authors: Rotem Sigall-Boneh, Arie Levine, Miranda Lomer, Nicolette Wierdsma, Philip Allan, Gionata Fiorino, Simona Gatti, Daisy Jonkers, Jarosław Kierkuś, Konstantinos H. Katsanos, Silvia Melgar, Elif Saritas Yuksel, Kevin Whelan, Eytan Wine, Konstantinos Gerasimidis

Although the current doctrine of IBD pathogenesis proposes an interaction between environmental factors and gut microbiota in genetically susceptible individuals, dietary exposures have attracted recent interest and are, at least in part, likely to explain the rapid rise in disease incidence and prevalence. The D-ECCO working group along with other ECCO experts with expertise in nutrition, microbiology, physiology, and medicine reviewed the evidence investigating the role of diet and nutritional therapy in the onset, perpetuation, and management of IBD. A narrative topical review is presented where evidence pertinent to the topic is summarised collectively under three main thematic domains: i] the role of diet as an environmental factor in IBD aetiology; ii] the role of diet as induction and maintenance therapy in IBD; and iii] assessment of nutritional status and supportive nutritional therapy in IBD. A summary of research gaps for each of these thematic domains is proposed, which is anticipated to be agenda-setting for future research in the area of diet and nutrition in IBD.

JCC: Volume 8, Issue 6, 2014Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
Year: 2014
Source: JCC: Volume 8, Issue 6, 2014
Authors: J.F. Rahier, F. Magro, C. Abreue, A. Armuzzi, S. Ben-Horin, Y. Chowers, M. Cottone, L. de Ridder, G. Doherty, R. Ehehalt, M. Esteve, K. Katsanos, C.W. Lees, E. MacMahon, T. Moreels , W. Reinisch, H. Tilg, L. Tremblay, G. Veereman-Wauters, N. Viget, Y. Yazdanpanah, R. Eliakim, J.F. Colombel

The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators. With such immunomodulation, the potential for opportunistic infection is a key safety concern for patients with IBD. Opportunistic infections pose particular problems for the clinician: they are often difficult to recognise and are associated with appreciable morbidity or mortality, because they are potentially serious and hard to treat effectively. This led the European Crohn's and Colitis Organisation (ECCO) to update the previous Consensus meeting on opportunistic infections in IBD.

JCC: Volume 12, Issue 7, 2018Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn’s Disease or Ulcerative Colitis
Year: 2018
Source: JCC: Volume 12, Issue 7, 2018
Authors: Karen Kemp, Lesley Dibley, Usha Chauhan, Kay Greveson, Susanna Jäghult, Katherine Ashton, Stephanie Buckton, Julie Duncan, Petra Hartmann, Nienke Ipenburg, Liesbeth Moortgat , Rosaline Theeuwen, Marthe Verwey, Lisa Younge, Andreas Sturm, Palle Bager

This is the second Nurses European Crohn’s and Colitis Organisation [N-ECCO] Consensus Statements document addressing inflammatory bowel disease [IBD] nursing across Europe. N-ECCO continues to be an active member of the European Crohn’s and Colitis Organisation [ECCO], providing education and networking opportunities for nurses across Europe within three designated nursing sessions, N-ECCO Network Meeting, N-ECCO School and the N-ECCO Research Forum, in addition to e-learning and podcasts.

JCC: Volume 10, Issue 3, 2016The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
Year: 2016
Source: JCC: Volume 10, Issue 3, 2016
Authors: Marcus Harbord, Vito Annese, Stephan R. Vavricka, Matthieu Allez, Manuel Barreiro-de Acosta, Kirsten Muri Boberg, Johan Burisch, Martine De Vos, Anne-Marie De Vries, Andrew D. Dick, Pascal Juillerat, Tom H. Karlsen, Ioannis Koutroubakis, Peter L. Lakatos, Tim Orchard, Pavol Papay, Tim Raine, Max Reinshagen, Diamant Thaci, Herbert Tilg, Franck Carbonnel

This is the first European Crohn’s and Colitis Organisation [ECCO] consensus guideline that addresses extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. It has been drafted by 21 ECCO members from 13 European countries. Although this is the first ECCO consensus guideline that primarily addresses EIMs, it is partly derived from, updates, and replaces previous ECCO consensus advice on EIMs, contained within the consensus guidelines for Crohn’s disease1 [CD] and ulcerative colitis2 [UC].

JCC: Volume 9, Issue 2, 2015The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
Year: 2015
Source: JCC: Volume 9, Issue 2, 2015
Authors: C.J. van der Woude, S. Ardizzone, M.B. Bengtson, G. Fiorino, G. Fraser, K. Katsanos, S. Kolacek, P. Juillerat, A.G.M.G.J. Mulders, N. Pedersen, C. Selinger, S. Sebastian, A. Sturm, Z. Zelinkova, F. Magro

Trying to conceive and being pregnant is an emotional period for those involved. In the majority of patients suffering from inflammatory bowel disease, maintenance therapy is required during pregnancy to control the disease, and disease control might necessitate introduction of new drugs during a vulnerable period. In this updated consensus on the reproduction and pregnancy in inflammatory bowel disease reproductive issues including fertility, the safety of drugs during pregnancy and lactation are discussed.

JCC: Volume 11, Issue 6, 2017Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Year: 2017
Source: JCC: Volume 11, Issue 6, 2017
Authors: Fernando Magro, Paolo Gionchetti, Rami Eliakim, Sandro Ardizzone, Alessandro Armuzzi, Manuel Barreiro-de Acosta, Johan Burisch, Krisztina B. Gecse, Ailsa L. Hart, Pieter Hindryckx, Cord Langner, Jimmy K. Limdi, Gianluca Pellino, Edyta Zagórowicz, Tim Raine, Marcus Harbord, Florian Rieder

This is the third European Crohn's and Colitis Organisation [ECCO] consensus guideline that addresses ulcerative colitis [UC]. It has been drafted by 28 ECCO members from 14 European countries. It is derived from and updates the previous ECCO consensus advice on UC. All the authors recognise and are grateful to previous ECCO members who contributed to creating the previous consensus guidelines on which some of the text is based. Attention is also drawn to other ECCO consensus guidelines which have contributed to this endeavour, on extra-intestinal manifestations [EIMs], malignancy, imaging, small bowel endoscopy, opportunistic infections [OIs], surgery, endoscopy, pathology, anaemia, reproduction and pregnancy, and paediatric UC.

Page: () 1 2 3 ()